# Elite AF IDE Trial (Elite AF)

Study · id `cardio:ct-nct07287436` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07287436](<https://clinicaltrials.gov/study/NCT07287436>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07287436

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 400 participants.

## Technical summary

Registry record NCT07287436. Allocation not applicable; no masking; primary purpose prevention. Start 2026-09-18 (actual); primary completion 2028-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT07287436, source copy `cardio:ctgov-nct07287436-2026-10-16`, retrieved 2026-10-26)
- Started: 2026-09-18 (actual) (ClinicalTrials.gov record NCT07287436, source copy `cardio:ctgov-nct07287436-2026-10-16`, retrieved 2026-10-26)
- Primary completion: 2028-01 (anticipated) (ClinicalTrials.gov record NCT07287436, source copy `cardio:ctgov-nct07287436-2026-10-16`, retrieved 2026-10-26)
- Completion: 2032-11 (anticipated) (ClinicalTrials.gov record NCT07287436, source copy `cardio:ctgov-nct07287436-2026-10-16`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07287436, source copy `cardio:ctgov-nct07287436-2026-10-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07287436-2026-10-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Elite AF IDE Trial (Elite AF)
- Condition: Atrial Fibrillation (AF)
- Condition: Stroke
- Intervention (Device): WATCHMAN Elite LAAC Device
- Lead sponsor: Boston Scientific Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: f0be28d11348080d10dbcf3b22f3a1b0659c5fd42e99def733e499b3ebb081f1
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
